MX2014005749A - Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). - Google Patents
Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp).Info
- Publication number
- MX2014005749A MX2014005749A MX2014005749A MX2014005749A MX2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A
- Authority
- MX
- Mexico
- Prior art keywords
- mmp
- nanocarriers
- diagnostic
- targeted therapeutic
- compositions
- Prior art date
Links
- 239000002539 nanocarrier Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565461P | 2011-11-30 | 2011-11-30 | |
| PCT/US2012/067236 WO2013082389A1 (en) | 2011-11-30 | 2012-11-30 | Mmp-targeted therapeutic and/or diagnostic nanocarriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014005749A true MX2014005749A (es) | 2014-06-05 |
Family
ID=47430071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005749A MX2014005749A (es) | 2011-11-30 | 2012-11-30 | Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8871189B2 (enExample) |
| EP (1) | EP2785635A1 (enExample) |
| JP (1) | JP2015502946A (enExample) |
| KR (2) | KR20150107894A (enExample) |
| CN (1) | CN104080729A (enExample) |
| BR (1) | BR112014012746A8 (enExample) |
| CA (1) | CA2854194A1 (enExample) |
| IL (1) | IL232824A0 (enExample) |
| MX (1) | MX2014005749A (enExample) |
| RU (1) | RU2014123622A (enExample) |
| WO (1) | WO2013082389A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014151988A1 (en) * | 2013-03-15 | 2014-09-25 | Mallinckrodt Llc | Matrix metalloprotease (mmp) targeted agents for imaging and therapy |
| CA2882268A1 (en) * | 2014-02-17 | 2015-08-17 | The Royal Institution For The Advancement Of Learning / Mcgill University | Polynucleotide-poly(diol) conjugates, process of preparation and uses thereof |
| US20160058705A1 (en) * | 2014-08-28 | 2016-03-03 | Jayakumar Rajadas | Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin |
| KR101683463B1 (ko) * | 2014-12-19 | 2016-12-08 | 서울대학교산학협력단 | 마이크로버블-리포좀-멜라닌 나노입자 복합체 및 이를 포함하는 조영제 |
| RU2646752C2 (ru) * | 2016-02-25 | 2018-03-07 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Ингибиторы цинк-зависимых металлопротеиназ (ММП-2 и ММП-9) в ряду бензоиламино(фенилсульфонил)-замещенных циклических аминокислот как потенциальные лекарственные средства, препятствующие постинфарктному ремоделированию левого желудочка сердца |
| CN110072531A (zh) | 2016-10-19 | 2019-07-30 | 阿维夫公司 | 用于治疗心血管相关疾病的爱帕琳的新型聚乙二醇化的脂质体制剂 |
| CN111004195B (zh) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | 卡巴他赛弱碱性衍生物及其制剂 |
| JP7842690B2 (ja) | 2020-02-19 | 2026-04-08 | ナミ セラピューティクス， インコーポレイテッド | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225181A (en) * | 1985-06-07 | 1993-07-06 | The Research Foundation Of State University Of New York | Radiolabeled antiplatelet monoclonal antibody for imaging in-vivo thrombi |
| US6750228B1 (en) * | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| FI113840B (fi) * | 2001-03-26 | 2004-06-30 | Ctt Cancer Targeting Tech Oy | Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa |
| FI20031528A0 (fi) * | 2003-10-17 | 2003-10-17 | Ctt Cancer Targeting Tech Oy | Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi |
| GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
| US20060210549A1 (en) | 2004-09-10 | 2006-09-21 | Srivastava Devendra K | Controlled release liposomes and methods of use |
| US20090022782A1 (en) | 2005-02-25 | 2009-01-22 | National University Corp. Hokkaido University | Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue |
| US20090246142A1 (en) | 2006-03-10 | 2009-10-01 | Massachusetts Institute Of Technology | Triggered Self-Assembly of Nanoparticles In Vivo |
| US7618992B2 (en) * | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| WO2010012473A2 (en) | 2008-07-30 | 2010-02-04 | Charite - Universitätsmedizin Berlin | Hydrolase-specific nanosensors, methods for producing them and uses in molecular imaging |
| WO2010022051A2 (en) | 2008-08-18 | 2010-02-25 | University Of Kansas | Disruptors of early/recycling endosomes |
| CA2757645C (en) | 2009-04-06 | 2018-05-15 | Mayo Foundation For Medical Education And Research | Methods and materials for delivering molecules |
| US9682151B2 (en) | 2009-07-15 | 2017-06-20 | The Regents Of The University Of California | Peptides whose uptake in cells is controllable |
| WO2011139343A2 (en) * | 2010-04-28 | 2011-11-10 | Wu Nian | Amino acid linked peg-lipid conjugates |
-
2012
- 2012-11-29 US US13/689,694 patent/US8871189B2/en not_active Expired - Fee Related
- 2012-11-30 CN CN201280067193.1A patent/CN104080729A/zh active Pending
- 2012-11-30 CA CA2854194A patent/CA2854194A1/en not_active Abandoned
- 2012-11-30 KR KR1020157024031A patent/KR20150107894A/ko not_active Withdrawn
- 2012-11-30 EP EP12806235.3A patent/EP2785635A1/en not_active Withdrawn
- 2012-11-30 KR KR1020147014186A patent/KR20140096080A/ko not_active Withdrawn
- 2012-11-30 JP JP2014544914A patent/JP2015502946A/ja active Pending
- 2012-11-30 BR BR112014012746A patent/BR112014012746A8/pt not_active IP Right Cessation
- 2012-11-30 WO PCT/US2012/067236 patent/WO2013082389A1/en not_active Ceased
- 2012-11-30 RU RU2014123622A patent/RU2014123622A/ru not_active Application Discontinuation
- 2012-11-30 MX MX2014005749A patent/MX2014005749A/es unknown
-
2014
- 2014-05-27 IL IL232824A patent/IL232824A0/en unknown
- 2014-09-18 US US14/490,357 patent/US20150004097A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014012746A2 (pt) | 2017-06-13 |
| CN104080729A (zh) | 2014-10-01 |
| KR20150107894A (ko) | 2015-09-23 |
| BR112014012746A8 (pt) | 2017-06-20 |
| WO2013082389A1 (en) | 2013-06-06 |
| US20130183236A1 (en) | 2013-07-18 |
| RU2014123622A (ru) | 2016-01-27 |
| CA2854194A1 (en) | 2013-06-06 |
| JP2015502946A (ja) | 2015-01-29 |
| KR20140096080A (ko) | 2014-08-04 |
| US20150004097A1 (en) | 2015-01-01 |
| IL232824A0 (en) | 2014-07-31 |
| US8871189B2 (en) | 2014-10-28 |
| EP2785635A1 (en) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284530A (en) | RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases | |
| IN2014CN03465A (enExample) | ||
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| JOP20120246B1 (ar) | مركبات و تركيبات كمثبطات كيناز c-Kit | |
| JO3002B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
| IN2014MN00948A (enExample) | ||
| AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
| MX346224B (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
| EA201400165A1 (ru) | Частицы на основе полиакрилата, которые содержат активное соединение | |
| UA114417C2 (uk) | Інгібітори iap | |
| BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
| BR112014012746A2 (pt) | nanoveículos de diagnóstico e/ou terapêutica direcionada por mmp | |
| MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| PH12013501163A1 (en) | Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer | |
| UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
| SG194235A1 (en) | Methods of predicting the development of complement-mediated disease | |
| PH12014502065A1 (en) | Vesicular formulations | |
| EP2767283A4 (en) | THERAPEUTIC AND PROPHYLACTIC AGAINST DEMYELINISING DISEASE | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| MX2014008194A (es) | Cefovecina util en el tratamiento de la enfermedad de lyme. | |
| BR112012006073A2 (pt) | composições e métodos para tratar espasticidade. | |
| GB201111427D0 (en) | Novel bisindolylmaleimides, pan-pkc inhibitors | |
| TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |